ICU Medical, Inc. (ICUI) AI Stock Analysis

ICU Medical, Inc., founded in 1984 and based in San Clemente, California, is a global medical device company specializing in infusion therapy and critical care applications. Its portfolio features needlefree connectors such as MicroClave and NanoClave, catheter patency tools like Neutron, disinfecting caps, and antimicrobial barrier caps. The company also supplies IV solutions including sodium chloride and balanced electrolyte solutions, alongside critical care products such as hemodynamic monitoring systems, cardiac output catheters, and blood pressure transducers. Additionally, it offers SafeSet closed blood sampling systems and ICU Medical MedNet IV medication safety software.

Revenue reached $2.23B in FY2025, down 6.4% from $2.38B in FY2024, but up from $1.32B in FY2021, reflecting a 5-year revenue CAGR of 11.9%. Gross margin widened to 36.8% in FY2025 from 34.6% in FY2024 and 30.6% in FY2022. Operating margin rose to 4.8% in FY2025, supporting net income of $732,000 and EPS of $7.32, compared to a net loss of $117.7M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 0.5% year-over-year, while quarterly earnings declined 46.9%. Over the trailing twelve months, revenue stood at $2.16B with a net profit margin of 1.4% and EPS of $1.19.

As of June 30, 2026, ICU Medical held $298.3M in cash and short-term investments against total debt of $1.27B, resulting in net debt of $973.3M. The company maintains a current ratio of 2.43, a debt-to-equity ratio of 0.59, and shareholders' equity of $2.15B across $3.97B in total assets. During FY2025, operating cash flow reached $179.8M and free cash flow was $91.8M. Capital allocation in FY2025 included $88.0M for capital expenditures and $8.8M for share buybacks, while share count expanded 14.8% over the past 5 years.

ICU Medical carries a market capitalization of $4.08B and an enterprise value of $5.00B. The stock trades at a trailing P/E of 137.0x, above the median of 24.6x for its US-listed Healthcare peers, though its forward P/E of 16.9x is slightly below the peer median of 17.3x. Its EV-to-EBITDA stands at 17.6x versus the peer median of 12.0x, while its price-to-sales multiple of 1.9x is lower than the peer median of 4.1x. Over the past year, the stock returned 39.9%, outperforming the S&P 500 (SPY) return of 16.8%, but its 5-year return of -29.4% trails the benchmark's 83.0% gain.

Wall Street sentiment shows 4 Strong Buy, 3 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $193.38 sits 18.6% above the last close of $162.99. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $2.19B and EPS of $8.75, representing 12.8% EPS growth. ICU Medical has exceeded EPS estimates in each of the last 4 quarters, with its next earnings release scheduled for November 5, 2026.

This page is an AI-written research summary of ICU Medical, Inc. (ICUI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ICUI income statement, ICUI balance sheet, ICUI key metrics, ICUI analyst forecast, ICUI chart. See the ICUI stock overview for the latest quote and news.